Sophia Xu

Properly understanding ADC PK/PD and in vivo stability is crucial to best inform clinical performance and trial design.

Don’t miss this session exploring bioanalytical strategy across development phases, insights into LCMS method development, and in vivo biotransformation impacting PK/PD and stability properties to understand how to efficiently leverage bioanalytical technologies to best characterize your ADC clinical material.

Workshop highlights include:

• Explaining the significance of ADC bioanalysis across reagent characterization and immunogenicity in early-stage ADC development
• Contextualizing bioanalytical analysis to understand clinical PK/PD consequences and impact on clinical development strategy
• Laying out regulatory expectations and emerging technologies for comprehensive ADC bioanalytical workflows across development phases